癌症疫苗迎来新纪元?KRAS抑制剂再添生力军... | AACR
▎药明康德内容团队编辑
2023年美国癌症研究协会(AACR)年会正在火热举行,AACR是全球范围内备受瞩目的癌症研究会议之一。多家医药公司已经汇报各自疗法的最新临床试验结果,新锐公司也展现了创新抗癌治疗模式的广阔前景。今天这篇文章里,药明康德内容团队将与读者分享AACR大会上部分公布的最新临床期和临床前研究结果。
新抗原癌症疫苗迎来新时代?
▲Moderna个体化癌症疫苗设计(图片来源:Moderna官网)
重磅免疫检查点抑制剂治疗肝癌、肺癌、胆管癌的最新结果
▲Imfinzi的3期临床试验结果(图片来源:阿斯利康官网)
靶向KRAS,礼来、信达生物公布最新结果
新治疗模式展现抗癌潜力
▲AFM13作用机制(图片来源:Affimed官网)
大家都在看
▲欲了解更多前沿技术在生物医药产业中的应用,请长按扫描上方二维码,即可访问“药明直播间”,观看相关话题的直播讨论与精彩回放
参考资料:
[1] Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA. Retrieved April 17, 2023, from https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in/
[2] Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine. Retrieved April 17, 2023, from https://ir.gritstonebio.com/static-files/26ff372a-8a0d-4268-a78d-06125393b8aa
[3] Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study. Retrieved April 17, 2023, from https://www.gene.com/media/press-releases/14987/2023-04-16/genentechs-tecentriq-plus-avastin-reduce
[4] Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial. Retrieved April 17, 2023, from https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-in-resectable-non-small-cell-lung-cancer.html
[5] Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer. Retrieved April 17, 2023, from https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-compared-to-chemotherapy-alone-in-patients-with-advanced-or-unresectable-biliary-tract-cancer/
[6] Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023. Retrieved April 17, 2023, from https://www.businesswire.com/news/home/20230417005257/en/
[7] AFFIMED PRESENTS FINAL DATA DEMONSTRATING SAFETY AND EFFICACY OF AFM13 PHASE 2 REDIRECT STUDY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2023. Retrieved April 17, 2023, from https://www.affimed.com/affimed-presents-final-data-demonstrating-safety-and-efficacy-of-afm13-phase-2-redirect-study-in-patients-with-heavily-pretreated-relapsed-or-refractory-peripheral-t-cell-lymphoma-at-the-american-asso/
[8] Halda Therapeutics Presents Preclinical Data for RIPTAC™ Therapeutics Demonstrating Oral Efficacy as a Monotherapy for the Treatment of Prostate Cancer. Retrieved April 17, 2023, from https://www.businesswire.com/news/home/20230417005221/en
[9] Prostate Cancer RIPTAC™ Therapeutics Demonstrate Activity in Preclinical Models of Enzalutamide-Resistant Prostate Cancer. Retrieved April 17, 2023, from https://haldatx.com/wp-content/uploads/2023/04/Halda-AACR-Poster-20230417.pdf
[10] AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'. Retrieved April 17, 2023, from https://www.fiercebiotech.com/biotech/lilly-challenges-amgen-mirati-early-kras-data-heading-field-much-less-crowded-it-seems
[11] CT030 - Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study. Retrieved April 17, 2023, from https://www.abstractsonline.com/pp8/#!/10828/presentation/10278
免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
分享,点赞,在看,聚焦全球生物医药健康创新